Risk Factors of Arthrogenic Muscle Inhibition - #AMR385

We’ve all seen it: the acute ACL patient who drags their leg into the clinic, unable to squeeze their quad to save their life. We call it Arthrogenic Muscle Inhibition (AMI), and for years, we’ve treated it as a stubborn, long-term enemy. But a fascinating new study from the American Journal of Sports Medicine suggests we might be overcomplicating it. Researchers analyzed 300 acute ACL patients and found that while AMI is incredibly common (affecting over half of patients), it’s also surprisi...